Cure8 trial brief
Long-term, real-world safety data help patients and clinicians understand risks — especially serious infections — when a newer ulcerative colitis drug is used in routine practice. This registry entry shows Pfizer is collecting 52-week safety information for velsipity.
Adults and caregivers of people with moderate-to-severe ulcerative colitis prescribed velsipity; clinicians prescribing velsipity; researchers tracking post-marketing safety of IL-23 inhibitors.
This ClinicalTrials.gov record describes an observational post-marketing safety study of velsipity 2 mg tablets in people with moderate-to-severe ulcerative colitis, run by Pfizer at a site in Tokyo.
The study will follow patients treated with velsipity in real-world practice for up to 52 weeks and focuses on collecting safety data, especially serious infections and adverse drug reactions.
The study is observational (non-interventional): patients already prescribed velsipity in usual care are enrolled and followed, rather than being randomized or assigned study treatments.
The planned enrollment and broader study conduct details are limited in the registry entry; the eligibility criteria exclude prior participants in clinical trials of the drug. The record lists a minimum age of 0 years and open sex eligibility, but local enrollment will follow site-specific consent and regulatory rules.
If you are taking velsipity or considering it, this study is intended to gather longer-term safety information from routine clinical use rather than to test efficacy compared with another treatment. It does not provide results; it is a study registration describing planned data collection.
The record is a trial registry (ClinicalTrials.gov) describing an observational safety study; it does not report results. Velsipity is identified in the record; confirm drug class and broader availability with your care team.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial is testing whether continued mirikizumab treatment helps children and teens with ulcerative colitis or Crohn’s disease achieve and maintain remission over the long term. Results could expand pediatric...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
This study will collect real-world data on adults with moderate-to-severe ulcerative colitis who start upadacitinib, tracking symptom remission and imaging response over one to two years — information that can help...
